Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per share and opened at $22.6 per share with a market capitalization of approximately $1.5 billion. Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to fund the company's development in the following Series B and Series C rounds. Before the company's IPO, Qiming Venture Partners held approximately 19.2% stake in Alamar and was one of its most important institutional investors. Founded in 2018, Alamar is a commercial-stage proteomics company dedicated to developing and commercializing proteomics technologies and establishing the gold standard in protein detection and analysis. Alamar's self-developed NULISA™ technology breaks through the design limitations of existing proteomics tools, delivering ultra-high sensitivity, high specificity, flexible multiplex protein detection, broad dynamic range and seamless automation to detect protein biomarkers at extremely low concentrations, filling a critical gap previously uncovered by other protein detection methods. In addition, the company's self-developed ARGO™ HT fully automated, high-throughput system enables a "sample-to-answer" automated workflow, driving rapid growth in product market penetration. As of the end of 2025, the ARGO™ HT system had accumulated an installed base of over 100 instruments, serving more than 300 customers across 25 countries. Since the commercialization of its platform, the number of scientific articles published based on its technologies and products has exceeded 100. "Congratulations to Alamar on its successful listing. We firmly believe that ultra-high-sensitivity proteomics will innovatively transform the future of early disease screening and precision diagnostics." said William Hu, Managing Partner of Qiming Venture Partners. "Guided by this original investment vision, we are delighted to have backed Alamar at an early stage and supported the company throughout its growth journey. We look forward to Alamar building on its world-leading proteomics platform to deliver earlier, more accurate and more accessible precision diagnostics, drive cutting-edge healthcare technologies into clinical practice to benefit the public, and create long-term value for global patients and the healthcare system." About Qiming Venture Partners Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others. 21% more press release views with Request a Demo

The new SV-Series Ventilators deliver adaptability, flexibility, and efficiency, redefining critical care solutions for clinicians worldwide. MAHWAH, N.J., March 18, 2026 /PRNewswire/ -- Mindray, a global leader in healthcare innovation across perioperative, medical imaging, and critical care, has announced its entry into the ventilator market with the launch of the SV900 and SV700 Ventilators. As the world's second-largest provider of acute care hospital ventilators, Mindray is leveraging its global expertise to make a powerful introduction to the North American market. This strategic expansion broadens Mindray's critical care portfolio, providing clinicians with adaptable, flexible, and efficient technology that delivers uncompromising care in high-pressure environments. Continue Reading The Mindray SV-Series sets a new standard in intelligent ventilation, empowering clinicians with deeper insights, adaptable technologies, and efficient workflows. Speed Speed The SV900 and SV700 Ventilators deliver adaptability, flexibility, and efficiency, supporting patients of all ages and respiratory needs across care settings. The SV900 and SV700 seamlessly integrate invasive, non-invasive, and high-flow oxygen therapies into a single device. "Entering the U.S. ventilator market with the SV900 and SV700 represents a pivotal moment in our company's growth and commitment to healthcare providers," said Wayne Quinn, President of Mindray North America. "We are enabling our partners to achieve significant economies of scale, streamline procurement processes, and enhance patient care by integrating our new respiratory solutions into our critical care portfolio and equipping their teams with a full suite of cutting-edge tools from a single, trusted provider." The SV900 and SV700 Ventilators deliver adaptability, flexibility, and efficiency, supporting patients of all ages and respiratory needs across care settings. They seamlessly integrate invasive, non-invasive, and high-flow oxygen therapies into a single device, streamlining workflows and ensuring the right level of support at every stage of recovery. With tools for weaning and lung-protective strategies, the SV-Series enhances clinical decision-making and helps to improve patient outcomes. In addition to these advanced clinical features, both ventilators are backed by an industry-leading three-year warranty, reflecting Mindray's unwavering dedication to long-term value and partnership. This coverage, part of Mindray's comprehensive total cost of ownership approach, ensures that healthcare providers benefit from exceptional quality, robust support, and ongoing service well beyond installation. Mindray's entry into the ventilator market marks a significant step in expanding advanced respiratory care options for clinicians and patients, reinforcing the medical device leader's commitment to driving innovation in healthcare. About Mindray Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities worldwide. At Mindray, we rise up to meet the highest standards possible because we believe everyone deserves access to quality healthcare. As a result, we have been advancing medical technologies for more than 30 years providing robust, best-in-class solutions that are focused on our customers and designed to address their biggest pain points. Mindray offers innovative, leading-edge, accessible perioperative, medical imaging, and critical care solutions, empowering healthcare professionals to provide the highest quality of care now and in the future. For more information, please visit . SOURCE Mindray North America 21% more press release views with Request a Demo

Engineers from the University of Hong Kong have developed an AI-assisted ultrasound lens that can clearly visualise the heart and lungs through the rib cage, opening the door to faster bedside diagnosis in emergency settings without relying on radiation-based scans. Dubbed SonoMeta, the ultrasound technology can capture images of the cardiac valve structures located up to approximately 10 centimetres behind the rib cage, the university noted in a media release. HOW IT WORKS The ultrasound lens is made up of metamaterials; it precisely controls ultrasound waves so that it penetrates the rib structures while reducing reflection and scattering. "The metamaterial provides the 'hardware' capability to shape sound waves," HKU Faculty of Engineering professor Nicholas X. Fang, who led the research team, explained to Mobihealth News . Meanwhile, the AI component of this imaging technology "provides the 'software' intelligence to determine the exact shape needed for each patient's unique anatomy," while eliminating individual variability and enabling dynamic zoom. "This combination enables personalised wavefront engineering that adapts to individual patients – something impossible with a fixed lens alone," Prof Fang noted. Its goal, the professor added, is "real-time signal reconstruction at the physical level, before any image is even formed, which fundamentally differs from post-processing image enhancement." Based on the HKU research team's validation study, SonoMeta achieved a penetration depth of at least 10 cm, a spatial resolution of less than 500 micrometres, and a 9.3 decibels increase in signal-to-noise ratio. This means, according to Prof Fang, that the ultrasound lens "enables visualisation of cardiac valve structures located up to 10 cm behind the rib cage with resolution approaching CT [computed tomography] quality, but with zero radiation and at the patient's bedside." WHY IT MATTERS Timely and accurate diagnoses of serious cardiac and thoracic conditions, such as myocardial infarction, heart failure, and pulmonary embolism, remain a challenge using traditional ultrasound examinations. To avoid the high impedance of rib bones, a conventional ultrasound exam of the heart, for instance, scans through narrow intercostal spaces, which, as a result, restricts and complicates the angles available for images of cardiac structure. On top of that, acoustic windows shrink by 30% in people who are obese, the elderly, or dealing with chronic obstructive pulmonary disease. Meanwhile, in chest examinations, traditional ultrasound also struggles to penetrate air-filled lung tissues and rib bones. For more accurate diagnoses, a doctor may refer a patient for X-rays or CT scans, which involve radiation exposure and may risk delaying critical treatment when ordered during emergencies. "Rib interference is a daily clinical limitation," Prof Fang emphasised. SonoMeta, then, serves as a solution to these long-standing challenges, the HKU research team said, with great potential clinical application in time-sensitive settings such as emergency rooms, intensive care units, and ambulances. It can facilitate immediate bedside cardiac assessment, allow the early detection of haemopericardium, and distinguish heart failure from pulmonary embolism, added Prof Fang. It also has potential deployment in community settings, where CT-like capability is uncommon. "Our goal is to make SonoMeta the world's first commercialised metamaterial-based ultrasound product, transforming bedside ultrasound from a 'window-dependent' tool into a 'window-independent' diagnostic powerhouse," the research lead said. WHAT'S NEXT The SonoMeta team has already completed principle validation, simulation modelling, and preclinical experiments. Multi-centre clinical trials are now underway at Ruijin Hospital in Shanghai, China, and United Christian Hospital in Hong Kong, specifically aiming to compare the metamaterial-based ultrasound against CT imaging. Prof Fang mentioned that almost 1,000 clinical datasets from heart failure patients and approximately 400 clinical datasets from neurodegenerative disease patients will be used for the ultrasound lens validation. The team is now developing a portable accessory that can be mounted on existing ultrasound probes, such as those developed by GE, Philips, and Mindray. The team is also pursuing a dual regulatory approval track with China's National Medical Products Administration and the United States Food and Drug Administration. Additionally, Prof Fang shared, the team plans to partner with manufacturers for an initial integration of their product before scaling into the high-margin aftermarket for clinical retrofit upgrades. Future iterations of the technology, the research lead said, may include transcranial as well as therapeutic applications.